AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) is a specialty pharmaceutical company that develops and commercializes medications in medically supervised settings. Two of the company's medicines for moderate-to-severe acute pain are DSUVIA and Zalviso. ARX-02 and ARX-03 are two forthcoming products from the firm.

Why should Investors make an Exit?

• Fall-in topline and continuous losses: ACRX witnessed a significant decline in total revenue to USD 2.82 million in FY21 (ended December 31, 2021) from USD 5.42 million in FY20. It is a loss-making entity and incurred a loss of USD 35.10 million in FY21 and USD 40.38 million in FY20 due to higher operating costs, resulting in negative profit margins.
• Macro Headwinds: Unless organic cash from normal business operations is robust, recent market discussions about raising interest rates sooner to combat inflation will pressure the corporation to increase short-term borrowing for working capital. This is a temporary stumbling hurdle that makes it less appealing to investors.
• Bearish Technical Indicator: On the daily chart, ACRX prices are sustaining below the downward sloping trend line and facing the resistance of the same. Furthermore, the momentum oscillator RSI (14-period) is trading at ~34.21. On the weekly chart, the prices are trading below the trend-following indicators 21-period and 50-period SMA, which may act as a resistance level for the stock.

Valuation Methodology: Price/Sales Multiple Based Relative Valuation

(Analysis by Kalkine Group)

* % Premium/(Discount) is based on our assessment of the company's FY1 trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.

Stock Recommendation:

ACRX's share price has remained on a bearish trend, fallen 82.41% in the past twelve months and is currently leaning close to the lower end of its 52-week range of USD 0.27 to USD 1.72. We have valued the stock using the Price/ Sales multiple based on relative valuation methodology and arrived at a target price of USD 0.23.

Based on the continuous losses, decline in topline, macro headwinds, current valuation, and bearish technical indicators, we recommend a "Sell" rating on the stock at the current price of USD 0.2832, up 1.36%, as of March 30, 2022.

Three-Year Technical Price Chart (as of March 30, 2022). Source: REFINITIV, Analysis by Kalkine Group

*All forecasted figures and Industry Information have been taken from REFINITIV.

*The reference data in this report has been partly sourced from REFINITIV.

Disclaimer

The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.